Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Craig A. Bunnell, MD, MPH
- Target Recruit Count
- 55
- Registration Number
- NCT00146588
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Center, Boston, Massachusetts, United States
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT00148135
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Docetaxel and Capecitabine in Advanced Gastric Cancer
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-04-18
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 80
- Registration Number
- NCT00142038
- Locations
- 🇩🇪
Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Dept. of Hematology and Oncology, Berlin, Germany
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT00142480
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
- Conditions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 50
- Registration Number
- NCT00130936
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 14
- Registration Number
- NCT00130507
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 876
- Registration Number
- NCT00130533
- Locations
- 🇪🇸
Hospital General Universitario Morales Meseguer, Murcia, Spain
🇪🇸Hospital Regional Universitario Carlos Haya, Málaga, Spain
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1384
- Registration Number
- NCT00129935
- Locations
- 🇪🇸
Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital General Universitario de Elda, Elda, Alicante, Spain
Tarceva and Capecitabine for Pancreatic Cancer
- Conditions
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00125021
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00124566
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.